iFrame is not supported! Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a novel Oncolytic virus that Codagenix, Inc is developing in the context of breast cancer. Oncolytic viruses in general are a relatively novel modality. These are live viruses (or live vaccines) engineered in a way that they can specifically infect and replicate, and cancer cells destroy some of these cancer cells and then trigger an anti-tumor immune response that ultimately alert the immune system to the cancer, fights it, and induces responses that can hopefully lead to durable responses in patients…
Author: Editor
Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a novel Oncolytic virus that Codagenix, Inc is developing in the context of breast cancer. Oncolytic viruses in general are a relatively novel modality. These are live viruses (or live vaccines) engineered in a way that they can specifically infect and replicate, and cancer cells destroy some of these cancer cells and then trigger an anti-tumor immune response that ultimately alert the immune system to the cancer, fights it, and induces responses that can hopefully lead to durable responses in patients and transform their lives.…
iFrame is not supported! LCMC3 Neoadjuvant Atezolizumab Phase 2 Study Results What is the LCMC3 (Lung Cancer Mutation Consortium) Trial? So, this is a consortium of academic institutions across the United States that collaborate with each other to conduct molecularly based clinical trials to advance the state of the art of lung cancer (neoadjuvant) therapy. What Is The Current Standard Of Care For Patients With Lung Cancer? The current standard of care for lung cancer has become very complex in clinical oncology, and I can’t review every aspect of it, but basically, there are two types of non-small…
LCMC3 Neoadjuvant Atezolizumab Phase 2 Study Results What is the LCMC3 (Lung Cancer Mutation Consortium) Trial? So, this is a consortium of academic institutions across the United States that collaborate with each other to conduct molecularly based clinical trials to advance the state of the art of lung cancer (neoadjuvant) therapy. What Is The Current Standard Of Care For Patients With Lung Cancer? The current standard of care for lung cancer has become very complex in clinical oncology, and I can’t review every aspect of it, but basically, there are two types of non-small cell lung cancer (NSCLC)…
iFrame is not supported! Lisocabtagene Maraleucel has been approved by the FDA for the second-line treatment of large B cell lymphoma LBCL Lisocabtagene Maraleucel Key Statistics: 65% risk reduction of event-free survival in the Lisocabtagene Maraleucel arm. 10.1 months (95% confidence interval: 6.1, not evaluable) estimated median event-free survival compared to 2.3 months (95% confidence interval: 2.2, 4.3). 59% risk reduction in progression-free survival in the Lisocabtagene Maraleucel arm compared to standard of care. Lisocabtagene Maraleucel is not approved to treat people with primary central nervous system lymphoma. Hazard ratio (HR) of 0.34 (95% CI:0.22, 0.52; p-value0.0001), event-free survival was…
iFrame is not supported! Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial 5 Key Conclusions: VS-6766 as a potential backbone of therapy for RAS pathway-driven cancers VS-6766 is a dual RAF/MEK with anti-tumor activity across multiple MAPK pathway alterations and multiple solid tumor indications VS-6766 + defactinib (FAKi) has shown 46% ORR (11/24) [64% ORR (7/11) in KRAS mt] with 23 months mPFS in LGSOC o Registration-directed clinical trial in progress (RAMP-201; NCT04625270) VS-6766 ± defactinib (FAKi) has shown 57% ORR (4/7) in KRAS G12V mt NSCLC o Registration-directed clinical trial…
iFrame is not supported! Is Interstitial Lung Disease a Manageable Adverse Event of Trastuzumab T-DXd Deruxtecan Treatment? What is Trastuzumab T-DXd? Trastuzumab T-DXd is an antibody-drug conjugate that consists of an antibody that binds to the HER-2 receptor that can be over-expressed or mutated in several different cancers. That is covalently linked to a payload. In this case, it’s a topoisomerase one inhibitor, a very potent chemotherapeutic drug, which has high toxicity typically when administered systemically. So there are advantages to the antibody-drug conjugate approach so that the payload is delivered preferentially to cells that express the HER-2 receptor. When…
iFrame is not supported! Biomarkers RNA: [2022] What Is ASPYRE Technology? How Can This Help Patients With Non-small Cell Lung Cancer (NSCLC)? I would like to speak with you today and tell you a little bit about ASPYRE and Biofidelity. So Biofidelity recently published a paper in BMC Medical Genomics describing a new technology called ASPYRE, and this really summarizes the low cost. A simple, very rapid assay for multi-molecule detection of multiple gene fusions from RNA. And the paper describes the assay for how detecting these fusions faster and at a lower cost has the potential to…
iFrame is not supported! KRAS G12C Sotorasib: [2022] An Updated Overview in CRC Update On The CodeBreaK 100 Trial/KRAS G12C Sotorasib The CodeBreaK 100 is a very large clinical trial that started with a safety study, phase 1, to define the recommended dose of Sotorasib (AMG 510) in patients with KRAS G12C-Mutations. This study was open for patients with non-small cell lung cancer (NSCLC), patients with colorectal cancer and all solid tumors with KRAS G12C-Mutation. The study initially defined that the 9/60 milligram dose of Sotorasib (AMG 510) once daily is the recommended dose to go further. It…
iFrame is not supported! IDE196 Solid Tumors GNAQ/11 Mutations or PRKC Fusions [2022] What is IDE196? And How Will It Help Patients With Solid Tumors? Recently, there have been phase 2 clinical data announcements regarding a subset of patients treated in the study. So there were 37 patients treated in a cohort of patients with DVA 300 milligrams twice daily and crizotinib 200 milligrams twice daily. So there were 35 invaluable patients, and excitingly, 89% of patients did have a decrease in their tumor, and the response rate was 50%. In order for half of the patients to achieve a…
iFrame is not supported! MIRAGE Trial Phase 3: CT / MRI SBRT Which is Better? [2022] Which is Better: CT or MRI SBRT in Prostate Cancer? So traditionally, radiation therapy, when it’s delivered in an external beam format, has relied on x-ray or CT-based imaging. MRI imaging provides very good space, full contrast, and resolution for certain targets, for example, targets in the pelvis such as the prostate. But historically, it has been technically difficult to integrate an MRI with a linear accelerator, which is what delivers the dose. High-energy x-rays and external beam radiotherapy There are two commercially…
Biomarkers RNA: [2022] What Is ASPYRE Technology? How Can This Help Patients With Non-small Cell Lung Cancer (NSCLC)? I would like to speak with you today and tell you a little bit about ASPYRE and Biofidelity. So Biofidelity recently published a paper in BMC Medical Genomics describing a new technology called ASPYRE, and this really summarizes the low cost. A simple, very rapid assay for multi-molecule detection of multiple gene fusions from RNA. And the paper describes the assay for how detecting these fusions faster and at a lower cost has the potential to really revolutionize patient care…
KRAS G12C Sotorasib: [2022] An Updated Overview in CRC Update On The CodeBreaK 100 Trial/KRAS G12C Sotorasib The CodeBreaK 100 is a very large clinical trial that started with a safety study, phase 1, to define the recommended dose of Sotorasib (AMG 510) in patients with KRAS G12C-Mutations. This study was open for patients with non-small cell lung cancer (NSCLC), patients with colorectal cancer and all solid tumors with KRAS G12C-Mutation. The study initially defined that the 9/60 milligram dose of Sotorasib (AMG 510) once daily is the recommended dose to go further. It was quite well tolerated…
IDE196 Solid Tumors GNAQ/11 Mutations or PRKC Fusions [2022] What is IDE196? And How Will It Help Patients With Solid Tumors? Recently, there have been phase 2 clinical data announcements regarding a subset of patients treated in the study. So there were 37 patients treated in a cohort of patients with DVA 300 milligrams twice daily and crizotinib 200 milligrams twice daily. So there were 35 invaluable patients, and excitingly, 89% of patients did have a decrease in their tumor, and the response rate was 50%. In order for half of the patients to achieve a partial response of greater…
MIRAGE Trial Phase 3: CT / MRI SBRT Which is Better? [2022] Which is Better: CT or MRI SBRT in Prostate Cancer? So traditionally, radiation therapy, when it’s delivered in an external beam format, has relied on x-ray or CT-based imaging. MRI imaging provides very good space, full contrast, and resolution for certain targets, for example, targets in the pelvis such as the prostate. But historically, it has been technically difficult to integrate an MRI with a linear accelerator, which is what delivers the dose. High-energy x-rays and external beam radiotherapy There are two commercially available MRI-guided linear accelerators…
7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to DCIS, or (invasive) ductal carcinoma insights, for several decades, we’ve recommended all women (diagnosed with Breast Cancer) who undergo lumpectomy receive radiation based on a 50% reduction in recurrence in the breast (cancer). We’ve tried to identify (DCIS) patients that don’t benefit from (adjuvant) radiation therapy, but using traditional clinical factors as well as pathologic factors has failed to identify a subset of residual risk patients that don’t benefit from radiation therapy with respect to local. The decision RT…
iFrame is not supported! Lung SBRT Dose Optimization [2022]: Overcoming Size & SUV? When Was Lung SBRT (stereotactic body radiation therapy) Treatment Developed? Lung SBRT (treatment) started in the late, 1990s, early 2000s. It was initially adapted in Japan, when radiation technology (using radiation beams) became, sophisticated enough to, instead of having one or two or three beams, coming from just a couple of directions aimed by an x-ray with a big giant rectangular target in the. As soon as the technology adapted the CT planning and controlling for tumor motion and allowing many beam angles so that you…
7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to DCIS, or (invasive) ductal carcinoma insights, for several decades, we’ve recommended all women (diagnosed with Breast Cancer) who undergo lumpectomy receive radiation based on a 50% reduction in recurrence in the breast (cancer). We’ve tried to identify (DCIS) patients that don’t benefit from (adjuvant) radiation therapy, but using traditional clinical factors as well as pathologic factors has failed to identify a subset of residual risk patients that don’t benefit from radiation therapy with respect to local. The decision RT…
Lung SBRT Dose Optimization [2022]: Overcoming Size & SUV? When Was Lung SBRT (stereotactic body radiation therapy) Treatment Developed? Lung SBRT (treatment) started in the late, 1990s, early 2000s. It was initially adapted in Japan, when radiation technology (using radiation beams) became, sophisticated enough to, instead of having one or two or three beams, coming from just a couple of directions aimed by an x-ray with a big giant rectangular target in the. As soon as the technology adapted the CT planning and controlling for tumor motion and allowing many beam angles so that you could shape the size…
iFrame is not supported! Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2 Clinical Trial) By Naval Daver, MD The study we are conducting here is a randomized phase 3 international study of Azacitidine Magrolimab (Hu5F9-G4), versus investigator choice therapy of either Azacitidine Venetoclax or intensive three plus seven, specifically in a molecular subset of TP53-mutated (TP53m), acute myeloid leukemia. The goal of this study is to see whether the combination treatment of…
iFrame is not supported! NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022] Nrg/RTOG 1112 A Randomized Phase III Study The NRG/RTOG 1112 (NRG Oncology RTOG 112) clinical trial focuses on patients with hepatocellular carcinoma, a group of patients who are understudied and in need of better treatments. At the start of this study, sorafenib was the standard of care for patients treated with locally advanced hepatocellular carcinoma that could not be removed and did not respond well to standard local ablation therapies or hepatic arterial regional therapies like TACE. And so that is why sorafenib is the backbone systemic…
iFrame is not supported! Cribriform CAP Intraductal Carcinoma Prostate [2022] Cribriform Prostate Cancer Clinical Trial I’m here to talk about our recent study, presented at ASTRO’s annual meeting. In this study, the gene expression or transcriptome characteristics of aggressive prostate cancer were looked at and found to be linked. morphologic appearance under the microscope as characterized by our genitor urinary pathologists, who are primary co-authors on the study. In particular, they were looking at this aggressive morphology or morphology associated with aggressive clinical behavior called cribriform or intraductal cancer of the prostate . The key findings from our…
iFrame is not supported! Genomic-Adjusted Radiation Dose Explained [2022] What Is Genomic-Adjusted Radiation Dose (GARD)? Genomic-Adjusted Radiation Dose (GARD) is a mathematical formalism that allows radiation oncologists to translate how much dose comes out of the radiation machine and into the patient and translate that into how much that will affect an individual patient. And it does that through a genetic signature of the tumor genome. And I think to anyone who’s (patients) treated radiation patients or any patients in the past. We all know intuitively that the same (radiotherapy prescription) dose doesn’t do the same thing to…
iFrame is not supported! What is The FAST-01 Clinical Trial in FLASH Radiotherapy About? It’s radiation that’s delivered at ultra high dose rates. FAST-01: 2022 5 Key Takeaways Is it possible to relieve the discomfort caused by painful bone metastases in the extremities with proton FLASH irradiation, which is provided at a dose rate that is 1000 times higher than the dose rate of conventional-dose-rate photon radiotherapy? Proton FLASH was therapeutically feasible and safe, with reduced severity of side effects, as established by this nonrandomized RCT of 10 patients with bone metastases in the extremities. The pain-relieving efficacy of the…
Male Breast Cancer: Clinical Signs [2022] What Are the Signs of Male Breast Cancer? And why do they go undetected? I think one thing that people don’t realize is that guys can actually get breast cancer. It is a relatively rare diagnosis, but that being said, we still see it. I think in the United States, there are about 2 to 3000 cases reported every year in men that develop breast cancer. When it comes to symptoms of breast cancer, most men have a breast lump that can be felt right under the nipple. I would say occasionally…
Breast Density Notification Rule: 2022 FDA: Dense Breasts The FDA Is Updating the Notification Rule For Women With Dense Breasts There’s been a lot of discussion recently about women with dense breasts and hiding cancers and the potential need for adding additional screening tests and also some new rules that will be coming out from the FDA, and I wanted to talk with you all about that. We know that mammography alone works pretty well. We should start screening every woman at least by age 40 if she has an average risk of breast cancer, and we find…
Male Breast Cancer: Clinical Signs [2022] iFrame is not supported! What Are the Signs of Male Breast Cancer? And why do they go undetected? I think one thing that people don’t realize is that guys can actually get breast cancer. It is a relatively rare diagnosis, but that being said, we still see it. I think in the United States, there are about 2 to 3000 cases reported every year. When it comes to symptoms of breast cancer, most men have a breast mass that can be felt right under the nipple. I would say occasionally a man will…
iFrame is not supported! Plinabulin addition to the DUBLIN-3 was a randomized phase III trial from BeyondSprings Pharmaceuticals in non-small cell lung cancer. It looked at an advanced non-small cell lung cancer, EGFR wild type. And I was looking at second and third-line treatment. Patients had to progress through at least one line of therapy, but two lines of progression were okay. And patients had to have been exposed to platinum-based therapy. The randomized clinical trial was pretty broad in that it took patients with an ECOG performance status of 2 or better, and they had to have measurable disease…
Breast Density Notification Rule: 2022 FDA: Dense Breasts iFrame is not supported! The FDA Is Updating the Notification Rule For Women With Dense Breasts There’s been a lot of discussion recently about women with dense breasts and hiding cancers and the potential need for adding additional screening tests and also some new rules that will be coming out from the FDA, and I wanted to talk with you all about that. We know that mammography alone works pretty well. We should start screening every woman at least by age 40 if she has an average risk of breast cancer,…
iFrame is not supported! Does Atezolizumab SBRT Improve Progression-Free Survival In NSCLC? Atezolizumab is an immune checkpoint inhibitor that targets PDL-1. It has been studied in a number of solid tumors, including non-small cell lung cancer, and is an approved treatment for non-small cell lung cancer that has spread to other parts of the body. It was also recently found to improve progression-free survival in patients with early-stage non-small cell lung cancer whose cancer had been removed. So, in S1914, we’re testing to see if adding neoadjuvant, concurrent, and adjuvant Atezolizumab SBRT (stereotactic body radiation therapy) randomized phase III trial…
Does Atezolizumab SBRT Improve Progression-Free Survival In NSCLC? Atezolizumab is an immune checkpoint inhibitor that targets PDL-1. It has been studied in a number of solid tumors, including non-small cell lung cancer, and is an approved treatment for non-small cell lung cancer that has spread to other parts of the body. It was also recently found to improve progression-free survival in patients with early-stage non-small cell lung cancer whose cancer had been removed. So, in S1914, we’re testing to see if adding neoadjuvant, concurrent, and adjuvant Atezolizumab SBRT (stereotactic body radiation therapy) randomized phase III trial for people with early-stage…
iFrame is not supported! What is The Phase III REPLATINUM Clinical Trial In Small Cell Lung Cancer (SCLC)? Interesting question, RRx-001 was tested in the phase III REPLATINUM clinical trial. Is it a new compound, and what has it been used for? So the answer to that is, absolutely, it is a new compound. There is nothing else like it. It is a traditional alkylating agent. But then, on alkylating cystines, not DNA protein cystines, it converts to a biologic agent and actually releases nitric oxide. As you were asking, the thing that’s probably most similar to it would…
REPLATINUM Phase III Update [2022] What is The Phase III REPLATINUM Clinical Trial In Small Cell Lung Cancer (SCLC)? Interesting question, RRx-001 was tested in the phase III REPLATINUM clinical trial. Is it a new compound, and what has it been used for? So the answer to that is, absolutely, it is a new compound. There is nothing else like it. It is a traditional alkylating agent. But then, on alkylating cystines, not DNA protein cystines, it converts to a biologic agent and actually releases nitric oxide. As you were asking, the thing that’s probably most similar to it would…
Genomic-Adjusted Radiation Dose Explained [2022] What Is Genomic-Adjusted Radiation Dose (GARD)? Genomic-Adjusted Radiation Dose (GARD) is a mathematical formalism that allows radiation oncologists to translate how much dose comes out of the radiation machine and into the patient and translate that into how much that will affect an individual patient. And it does that through a genetic signature of the tumor genome. And I think to anyone who’s (patients) treated radiation patients or any patients in the past. We all know intuitively that the same (radiotherapy prescription) dose doesn’t do the same thing to each patient (radiotherapy benefit).…
Hello Test iFrame is not supported! Hello Below
Cribriform CAP Intraductal Carcinoma Prostate [2022] Cribriform Prostate Cancer Clinical Trial I’m here to talk about our recent study, presented at ASTRO’s annual meeting. In this study, the gene expression or transcriptome characteristics of aggressive prostate cancer were looked at and found to be linked. morphologic appearance under the microscope as characterized by our genitor urinary pathologists, who are primary co-authors on the study. In particular, they were looking at this aggressive morphology or morphology associated with aggressive clinical behavior called cribriform or intraductal cancer of the prostate . The key findings from our study were that in…
NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022] Nrg/RTOG 1112 A Randomized Phase III Study The NRG/RTOG 1112 (NRG Oncology RTOG 112) clinical trial focuses on patients with hepatocellular carcinoma, a group of patients who are understudied and in need of better treatments. At the start of this study, sorafenib was the standard of care for patients treated with locally advanced hepatocellular carcinoma that could not be removed and did not respond well to standard local ablation therapies or hepatic arterial regional therapies like TACE. And so that is why sorafenib is the backbone systemic therapy that’s used in…
Prioritizing Screening Mammogram: Help Early Diagnosis? Mammography (breast imaging) is one of the most commonly used preventive healthcare services (annual mammogram). However, with the recent rise of breast cancer, more and more women are asking their doctors about screening annual mammograms (scheduling baseline mammograms). What is the difference between an immediate and a delayed mammogram? How should you go about choosing which type of mammography to have? This article will talk about these questions and give you some tips on how to decide which screening mammograms are most important and get a immediate mammographic interpretation. Screening mammograms (SMs) or Breast…
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody-drug conjugates (ADCs) therapy may play a role. Claim credit: https://www.achlcme.org/tnbc-case-challenge-onctube Access the three-part series: https://www.achlcme.org/triple-negative-breast-cancer
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series. Claim credit: https://www.achlcme.org/PARPis-tnbc-onctube Access the three-part series: https://www.achlcme.org/triple-negative-breast-cancer
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test in these interactive case challenges. As the third and final activity in the TNBC series, you will navigate through two cases. Education is built into the cases, on practical strategies to meet the treatment needs of diverse patients with TNBC. Access the full case study: https://www.achlcme.org/tnbc-case-challenge-onctube View the three-part series:Â https://www.achlcme.org/triple-negative-breast-cancer
With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary team approach to caring for patients. As precision medicine continues to evolve in cancer care, the integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches. This series offers two interactive programs supported by audio and video commentary, where expert faculty share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:• Increase implementation of best practices for EGFR mutation…
rAd-IFNα/Syn3 Phase 3 Trial NMIBC [2022] rAd-IFNα/Syn3 Bladder Cancer Trial It’s an honor to be asked to speak about this medication, which is a very exciting new development for many patients with non muscle-invasive bladder cancer. So RAD interferon alpha CIN 3 is a compound that links. The adenoviral vector RAD alpha interferon to an excipient CIN 3, which helps transduction of the adenovirus into bladder cancer cells. So it is a new compound. It was developed in conjunction by Dr. Colin Denney from MD Anderson with FKD Therapeutics, a company in Finland. And it was, as we’ll talk…
CHECKMATE-914 Phase 3 Dr. Brian Rini, MD [2022] CHECKMATE-914 Trial The purpose of this study is to determine if the use of Nivolumab on its own or in combination with Ipilimumab and Nivolumab, as opposed to the use of a placebo, is both safe and beneficial for postponing or preventing the recurrence of cancer in patients who have had a kidney removed. Â The key outcomes of this study are measured in two different ways. The first principal completion date is anticipated to take place in July 2022. (DFS in Part A). The second primary completion date is anticipated to…
Prophylactic management of hemophilia continues to be a challenge. This nurse-led activity discusses treatment strategies, safety and efficacy of current available products, and how to improve patient adherence. In this clinical commentary, expert faculty, Kerry H. Hansen, RN, BS and Skye Peltier, MPH, PA-C review best practices to facilitate successful therapeutic interventions with hemophilia A prophylaxis. Claim credit: https://www.achlcme.org/hemophilia-a-prophylaxis-onctube
CHECKMATE-914 Phase 3 Kidney Cancer Trial [2022] CHECKMATE-914 Trial I’m going to talk to you today about CHECKMATE-914 clinical trial, which was an adjuvant study of Ipilimumab plus Nivolumab (in combination) in high risk resected kidney cancer. Â The background of this study (CHECKMATE-914 trial) is that About a year or so ago, we had the first data for adjuvant (treatment) immun0therapy and kidney cancer (localized renal cell carcinoma RCC), which was from the keynote study of adjuvant Pembrolizumab versus placebo and resected, high risk localized kidney cancer. That study (CHECKMATE-914 trial) and its follow up showed a significant disease-free…
COSMIC-313 Phase 3 Kidney Cancer Trial [2022] COSMIC-313 Kidney Cancer Trial I’m going to talk today about COSMIC-313 ( Ipi/Nivo (Nivolumab and Ipilimumab)), which is a clinical trial just reported as more of the latest phase 3 data in advanced kidney cancer (advanced renal cell carcinoma). Â The background of the COSMIC-313 ( Ipi/Nivo (Nivolumab and Ipilimumab)) study: this was a study looking at Ipi/Nivo (Nivolumab and Ipilimumab) as a comparison arm, which, as you probably know, are two immune therapy drugs that are a common frontline treatment (components) in advanced RCC (advanced renal cell carcinoma). And it was compared…
Breast Cancer Screening [2022]: What Are We Missing? Are Women Avoiding Breast Cancer Screening? Because of COVID-19 and the subsequent lockdowns, a significant number of women were either unable to get their yearly mammograms (primary breast cancer screening tests) or did not feel it was safe to get their regular screening. And why, if they were screened, do such a large number of women still lack a diagnosis? The concept that women with dense breasts are misidentified as having the condition was investigated further through these clinical studies. Screening with mammography according to industry standards is insufficient for early detection,…
UCSF With FDA In Robotic Colorectal Surgery Trial: da Vinci SP [2022] Â The da Vinci SP Surgical Systems So the daVinci is the robotic platform for a company called Intuitive. The daVinci has been around since 1999 and has had several generations of robots. Their most recent generation, which is ubiquitous around the US and increasingly being picked up around the world, is called the XI platform, and this is a multiport platform. Â There are two types, one has four robotic arms. I can show a picture if you are interested. But it has four arms that go…
Shahid Gilani, MD, Specialist doctor in Clinical Oncology from University Hospital of North Midlands, speaks about the Cancer Associated Thrombo-prophylaxis. Dedicated Cancer Associated Service @UNHM_NHS @sngilani